A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Repaglinide

Glinide class · 4 generic manufacturers · 12 ANDAs filed at FDA.

First FDA approval2013-11-22
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$17.5M in CY2024 Part D spend548K claims · 171K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.080/unit
17 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.082
Across all dosage forms in distribution.
Highest NADAC
$0.086
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Repaglinide used for?

Repaglinide is a Glinide medication tracked in Medicare Part D.

Is there a generic for Repaglinide?

Yes. 12 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Repaglinide?

Across 329 Part D plans, Repaglinide averages $0.082/unit (NADAC). Lowest available: $0.080/unit. Highest in distribution: $0.086/unit.

Is Repaglinide on the FDA shortage list?

No. Repaglinide is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Glinide1 alternative in D1
01
Nateglinide
Glinide
$0.178Lowest NADAC
6Generic mfrs
$12.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (17 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.